X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and toddlers from respiratory syncytial virus, which is investigating in PII trial for the prevention of respiratory syncytial virus in protect infants and toddlers.
Lead Product(s): MV-012-968
Therapeutic Area: Infections and Infectious Diseases Product Name: MV-012-968
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and young children from RSV. Safety data show that MV-012-968 is highly attenuated, with no serious adverse events reported.
Lead Product(s): Live Attenuated RSV Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MV-012-968
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
MV-014-212, the company’s intranasal recombinant live attenuated COVID-19 vaccine is designed for global use to block transmission, provide durable protection, and control SARS-CoV-2 spread and variants.
Lead Product(s): Recombinant Live Attenuated COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MV-014-212
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands.
Lead Product(s): MV-014-210
Therapeutic Area: Infections and Infectious Diseases Product Name: MV-014-210
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
With Fast Track Designation, Meissa is eligible for early and frequent interactions with FDA reviewers to discuss all aspects of the clinical development plan for MV-012-968.
Lead Product(s): MV-012-968
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
